Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 17/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.92 |
| ▸ | MAPT | P10636 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | GALR3 | O60755 | 1/20 | 0.77 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456998 | 0.88 | GALR3 (1.00) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL3765851 | 0.87 | FAAH (0.77) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL3764536 | 0.87 | FAAH (1.00) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL5275554 | 0.87 | FAAH (0.77) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL3766339 | 0.87 | FAAH (1.00) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL5060772 | 0.86 | FAAH (0.76) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL4458573 | 0.86 | FAAH (0.76) | FAAHPOLBMAPTMAPK1GALR3 | |
| SCHEMBL3765816 | 0.86 | FAAH (0.80) | FAAHPOLBMAPTMAPK1 | |
| SCHEMBL1164398 | 0.85 | FAAH (1.00) | FAAH | |
| SCHEMBL13823969 | 0.85 | FAAH (0.74) | FAAHPOLBMAPTMAPK1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | claimed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-7541359-B2 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-7541359-B2 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007005510-A1 | N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | APODACA RICHARD | 2007-01-04 | — | — | US | disclosed |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | APODACA RICHARD | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885POLB 2770/4885MAPT 3805/4885 |
| US-20070004741-A1 | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, CNR2 | FAAH 1/4885POLB 1961/4885MAPT 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.